A Post Marketing Evaluation of the Effectiveness of FluMist Risk Minimization Plan in Children

1

Children less than 24 months of age

Medicamento: No Intervention

There were no interventions. No subjects were enrolled in this retrospective database study.

2

Children 24 to 59 months of age with a claim associated with a diagnosis of asthma

Medicamento: No Intervention

There were no interventions. No subjects were enrolled in this retrospective database study.

3

Children 24 to 59 months of age without a claim associated with a diagnosis of asthma, but with dispensed medication for wheezing

Medicamento: No Intervention

There were no interventions. No subjects were enrolled in this retrospective database study.

4

Children 24-59 months of age with immunosuppression

Medicamento: No Intervention

There were no interventions. No subjects were enrolled in this retrospective database study.

FluMist Use in Participants up to 59 Months of Age

Among participants up to 59 months of age who received any flu vaccine, number who received FluMist

Vaccinating Physician Specialty: Pediatrician or Pediatric Specialist

Specialty of vaccinating physician who provided FluMist.

Vaccinating Physician Specialty: General/Family Practitioner

Specialty of vaccinating physician who provided FluMist

Vaccinating Physician Specialty: Other

Specialty of vaccinating physician who provided FluMist

Vaccinating Physician Specialty: Unknown

Specialty of vaccinating physician who provided FluMist

Geographic Region: Northeastern

Geographic region of parents' residence among participants receiving FluMist

Geographic Region: North Central

Geographic region of parents' residence among participants receiving FluMist

Geographic Region: Southern

Geographic region of parents' residence among participants receiving FluMist

Geographic Region: Western

Geographic region of parents' residence among participants receiving FluMist

Number of Outpatient Visits: 0

Among participants vaccinated with FluMist, the number who had 0 outpatient visits in the 3 months prior to vaccination

Number of Outpatient Visits: 1

Among participants vaccinated with FluMist, the number who had 1 outpatient visit in the 3 months prior to vaccination

Number of Outpatient Visits: 2 or More

Among participants vaccinated with FluMist, the number who had 2 or more outpatient visits in the 3 months prior to vaccination

Number of Days With a Respiratory Claim in 28 Days Prior to Vaccination: 0

Among participants vaccinated with FluMist, the number of days with a respiratory claim (asthma, acute respiratory distress, bronchospasm, influenza, respiratory syncytial virus, bronchiolitis, bronchitis, pneumonia, croup, sinusitis, adenovirus infection, coxsackie virus infection, rhinovirus infection, nasopharyngitis, laryngitis and tracheitis, upper respiratory infection, cough) in the 28 days prior to vaccination.

Number of Days With a Respiratory Claim in 28 Days Prior to Vaccination: 1

Among participants vaccinated with FluMist, the number of days with a respiratory claim (asthma, acute respiratory distress, bronchospasm, influenza, respiratory syncytial virus, bronchiolitis, bronchitis, pneumonia, croup, sinusitis, adenovirus infection, coxsackie virus infection, rhinovirus infection, nasopharyngitis, laryngitis and tracheitis, upper respiratory infection, cough) in the 28 days prior to vaccination.

Number of Days With a Respiratory Claim in 28 Days Prior to Vaccination: 2 or More

Among participants vaccinated with FluMist, the number of days with a respiratory claim (asthma, acute respiratory distress, bronchospasm, influenza, respiratory syncytial virus, bronchiolitis, bronchitis, pneumonia, croup, sinusitis, adenovirus infection, coxsackie virus infection, rhinovirus infection, nasopharyngitis, laryngitis and tracheitis, upper respiratory infection, cough) in the 28 days prior to vaccination.